TY - JOUR
T1 - Conditionally replicative adenoviral vectors for cancer gene therapy
AU - Gómez-Navarro, Jesús
AU - Curiel, David T.
N1 - Funding Information:
We thank Enrique Casado for his useful comments on the manuscript, and Hidde Haisma (Department of Medical Oncology, Gene Therapy Division, University Hospital VU Amsterdam, Netherlands) for facilitating Figure 1 . This work is supported by grants from the National Institutes of Health R01 CA83821, the US Department of Defense PC970193, the US Department of Defense PC 991018, the Susan Komen Foundation, and the CapCURE Foundation to DT Curiel and DAMD 17-001-0116 to Jesus Gomez-Navarro.
PY - 2000/11/1
Y1 - 2000/11/1
N2 - During the past century, many attempts have been made to exploit the ability of some viruses to infect and destroy cancer cells. Crippled, non-replicative viruses have been used as vectors to transfer genes into tumours. Both strategies have serious limitations. The time is now ripe, however, for full convergence of these two research tracks. On the one hand, the intratumoral propagation of replicative viruses would overcome the low levels of gene transfer achieved by current viral vectors. On the other hand, the versatility provided by vectors encoding foreign genes, which are limited in their uses only by our ingenuity, would overcome the physiological barriers to robust propagation of the viral progeny in the tumour. This empowering synthesis will provide truly new opportunities that might realise the promises of gene transfer for the therapy of cancer.
AB - During the past century, many attempts have been made to exploit the ability of some viruses to infect and destroy cancer cells. Crippled, non-replicative viruses have been used as vectors to transfer genes into tumours. Both strategies have serious limitations. The time is now ripe, however, for full convergence of these two research tracks. On the one hand, the intratumoral propagation of replicative viruses would overcome the low levels of gene transfer achieved by current viral vectors. On the other hand, the versatility provided by vectors encoding foreign genes, which are limited in their uses only by our ingenuity, would overcome the physiological barriers to robust propagation of the viral progeny in the tumour. This empowering synthesis will provide truly new opportunities that might realise the promises of gene transfer for the therapy of cancer.
UR - http://www.scopus.com/inward/record.url?scp=0034334615&partnerID=8YFLogxK
U2 - 10.1016/s1470-2045(00)00030-9
DO - 10.1016/s1470-2045(00)00030-9
M3 - Review article
C2 - 11905653
AN - SCOPUS:0034334615
SN - 1470-2045
VL - 1
SP - 148
EP - 158
JO - Lancet Oncology
JF - Lancet Oncology
IS - 3
ER -